Transplant Medicine
Combination therapy is problematic after hepatitis C-related liver transplants
Published in Hepatitis Weekly, August 8th, 2005
According to a study from Canada, "recurrent hepatitis C (HCV) after liver transplantation (LT) is often more aggressive and treatments tend to be less successful. Pegylated-interferon and ribavirin are the standard of care for the treatment of HCV; however, there is limited published experience of its use after LT."
M. Babatin and colleagues, University of Calgary conducted a study "to report the results of pegylated-interferon alpha 2b (PEG-IFN) plus ribavirin for the treatment of recurrent HCV after LT and compare the results with published data. Thirteen patients with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-08-08)
More Articles from Hepatitis Weekly
- Endocrinology
Insulin resistance triggers hepatitis C-related liver steatosis and fibrosis - Hepatitis B Virus
Occult hepatitis B may hamper interferon in hepatitis C coinfected patients - Hepatitis C Therapy
Short courses of peginterferon clear hepatitis C genotypes 2 or 3 - Rheumatology
Hepatitis C virus infection is not a cause of fibromyalgia - Allergy & Immunology
Innate immunity overwhelms adenoviral gene expression in the liver - Avian Influenza
International health entity stresses threat from Avian influenza has not ebbed - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
